Development of Oral Small Molecule PCSK9 Antagonist
口服小分子PCSK9拮抗剂的研制
基本信息
- 批准号:9346559
- 负责人:
- 金额:$ 68.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAdverse effectsAnimal BehaviorAnimal ModelBindingBinding ProteinsBioavailableBiochemistryBiological AssayBiological AvailabilityBloodCardiovascular DiseasesCardiovascular systemCause of DeathCellsCholesterolCholesterol HomeostasisClinicalClinical TrialsCodeCoronary ArteriosclerosisCytochrome P450Degradation PathwayDevelopmentDietDoseDrug CompoundingDrug KineticsEducationEndoplasmic ReticulumEnsureEnzyme PrecursorsEpidemicEpidermal Growth FactorEpidermal Growth Factor ReceptorEvaluationEventExhibitsFamilial HypercholesterolemiaFatty acid glycerol estersFemaleFormulationGenesGoalsHeart DiseasesHemolysisHigh Density LipoproteinsHigh Fat DietIn VitroIndividualInterventionLDL Cholesterol LipoproteinsLabelLeadLinkLipidsLiverLow Density Lipoprotein ReceptorLow-Density LipoproteinsMethodsModelingMolecular ChaperonesMorbidity - disease rateMusNonsense MutationOralOrganOryctolagus cuniculusPatientsPeptide HydrolasesPermeabilityPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacotherapyPhasePlasmaPlasma ProteinsPopulationProtein PrecursorsRecombinantsRiskRisk FactorsRouteSafetySequence AnalysisSourceSubtilisin Like Proprotein ConvertasesSurfaceTestingToxicologyWomanWorkanalogbasecytotoxicitydrug candidatedrug marketefficacy testingextracellulargain of function mutationhigh riskhistopathological examinationhypercholesterolemiaimprovedin vivokillingslipid disorderloss of functionloss of function mutationmalemenmortalitynanocrystalnanoformulationnanomolarnovelpre-clinicalprematureprogramsscreeningsmall moleculesubcutaneoustherapeutic targettraffickinguptakevirtual
项目摘要
Project Summary/Abstract:
The epidemic of cardiovascular disease (CVD) is a global phenomenon that remains the number one cause of
death throughout the world, killing nearly 17.3 million people per year; a number that is expected to grow to
23.6 million by 2030. A high cholesterol level is well-known risk factors for heart disease. Although blood
cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only
38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the
National Cholesterol Education Program (NCEP). Furthermore, patients with homozygous familial
hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapy,
and are at very high risk of premature cardiovascular disease. These and other patients will dramatically
benefit from an aggressive treatment of hypercholesterolemia. The long-term goal of this work is to develop
novel orally bioavailable drugs for cholesterol lowering. Our therapeutic target is the protease proprotein
convertase subtilisin-like kexin type 9 (PCSK9). PCSK9 controls the degradation of the LDL receptor (LDLR) in
the liver and thereby contributes to cholesterol homeostasis. PCSK9 is synthesized as a precursor protein that
undergoes processing. Secreted PCSK9 binds to the LDL-receptor (LDLR) and chaperones it to the
degradation pathway. To achieve our goal, we identified nanomolar orally active small molecule PCSK9/LDLR
antagonists and demonstrated its efficacy in animal model. As part of this Phase-II proposal, we will undertake
all the work required to characterize these compounds in multiple animal models for the proof of concept and
conduct safety assessment in order to advance the lead compound toward IND-enabling studies and clinical
trials.
项目概要/摘要:
心血管疾病(CVD)的流行是一种全球现象,仍然是心血管疾病的头号原因。
全世界每年有近1730万人死亡,预计这一数字将增长到
23.6到2030年,亿。高胆固醇水平是众所周知的心脏病危险因素。虽然血
胆固醇可以使用许多市售药物来降低,其中他汀类药物是主要药物,
38%的服用这些药物的患者正在实现低密度脂蛋白胆固醇的目标,
国家胆固醇教育计划(NCEP)。此外,纯合子家族性
胆固醇水平显著升高的高胆固醇血症对目前的药物治疗反应差,
而且患早发心血管疾病的风险很高。这些病人和其他病人将戏剧性地
从高胆固醇血症的积极治疗中获益。这项工作的长期目标是发展
用于降低胆固醇的新型口服生物可利用药物。我们的治疗目标是蛋白酶前蛋白
转化酶枯草杆菌蛋白酶样kexin 9型(PCSK 9)。PCSK 9控制LDL受体(LDLR)的降解,
从而有助于胆固醇的体内平衡。PCSK 9作为前体蛋白合成,
进行加工。分泌的PCSK 9与LDL受体(LDLR)结合,并伴随其与
降解途径为了实现我们的目标,我们鉴定了纳摩尔口服活性小分子PCSK 9/LDLR
拮抗剂,并证明其在动物模型中的功效。作为第二阶段提案的一部分,我们将
在多个动物模型中表征这些化合物以验证概念所需的所有工作,
进行安全性评估,以推进先导化合物的IND研究和临床
审判
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nabil A Elshourbagy其他文献
Renal ATP Citrate Lyase (ATP CL) Protein Localizes throughout the Nephron and Increases Only in the Proximal Tubule with Chronic Metabolic Acidosis (CMA)
肾型 ATP 柠檬酸裂合酶(ATP CL)蛋白定位于整个肾单位,且仅在慢性代谢性酸中毒(CMA)时在近端小管中增加
- DOI:
10.1203/00006450-199904020-01996 - 发表时间:
1999-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Krishna Puttaparthi;Thomas Rogers;Nabil A Elshourbagy;Moshe Levi;Joel Z Melnick - 通讯作者:
Joel Z Melnick
Nabil A Elshourbagy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nabil A Elshourbagy', 18)}}的其他基金
Oral PCSK9/LDLR antagonist direction to the clinic
口服 PCSK9/LDLR 拮抗剂临床指导
- 批准号:
9906738 - 财政年份:2020
- 资助金额:
$ 68.23万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 68.23万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 68.23万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 68.23万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 68.23万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 68.23万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 68.23万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 68.23万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 68.23万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 68.23万 - 项目类别: